Catalyst Event

Moderna Inc (MRNA) · Other

From Akros U.S. Large Cap 500 Protective Allocation Monthly Index (A500PAM)

5/28/2026, 12:00:00 AM

OtherSentiment: Positive

An FDA advisory committee (VRBPAC) to vote on recommending a monovalent XFG vaccine for the 2026-2027 COVID-19 season on May 28, 2026, a strain for which Moderna has presented positive immunogenicity data; Low importance as advisory committee votes are preliminary and usually result in 1-5% impact, scheduled.

Korean Translation

2026년 5월 28일 FDA 자문위원회(VRBPAC)의 2026-2027년 코로나19 시즌용 단가 XFG 발신 권고 투표; 모더나가 긍정적인 면역원성 데이터를 발표한 글주이며, 자문위 권고는 예비적 단계로 1-5%의 영향이 예상되어 중요도를 'Low'로 설정함, 예정됨.

Related Recent Events

View Full Timeline